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Sunday, April 23, 2017 
 
16:00 – 17:15 Conference Check-in  
 
17:30 – 18:30 Dinner 
 
18:30 – 19:00 Opening comments 
 
19:00 – 20:00 Keynote Speaker 1 – Harnessing Science and Technology to Accelerate High Impact 
Drug Discovery 
Dr. Ron dePinho, CEO, MD Anderson Cancer Center  
 
20:00 – 21:00 Keynote Speaker 2 – Opportunities to Improve Global Human Health 
Katey Owen, Director, The Bill & Melinda Gates Foundation 
 








 Locations for the technical and poster sessions will be announced on site. 
 All meals will be in the Riverside Hearth Restaurant.  
 Audiotaping, videotaping and photography of presentations are prohibited. 
 
 Speakers – Please leave at least 5 minutes for questions and discussion. 
 
 Speakers – Please ensure your talk adheres to your given time allotment.  Talks that go over their 
allotment reduce time for valuable discussion and can disrupt the conference program. 
 
 Turn your cellular telephones to vibrate or off during technical sessions. 
 
 After the conference, ECI will send an updated participant list to all participants.  Please check your 
listing now and if it needs updating, you may correct it at any time by logging into your ECI account.  
 
 Please do not smoke at any conference functions. 
 
 Please write your name in the front of this program booklet so it can be returned if misplaced. 
 
  
Monday, April 24, 2017 
 
07:30 – 08:30 Breakfast 
 
08:30 – 12:00 Oral Session 1 – Vaccines – Rapid Responses to Global Health Challenges 
Chair: Vijay Yabannavar, Vice President, Technical Operations Merck & Co Inc/MSD 
 
08:40 – 09:30 Plenary Lecture – Rapid response to the Ebola crisis 
Jayanthi Wolf, Director Global Regulatory Affairs, Merck & Co Inc/MSD 
 
09:30 – 10:00 Facilitation of a rapid response by self-amplifying mRNA vaccines 
Jeffrey B. Ulmer, GSK Vaccines 
 
10:00 – 10:30 Coffee break (Sponsored by Pfizer) 
 
10:30 – 11:00 Platforms prepare manufacturing for rapid responses,  
Jeffrey Welch, Emergent Biosolutions 
  
11:00 – 11:30 Rapid vaccine responses to emerging pathogens using a platform technology 
                                Tim Hahn, Novavax 
 
11:30 – 12:00 Rapid response to pandemic influenza using a licensed recombinant seasonal influenza 
vaccine platform 
Penny Post, Protein Sciences 
 
12:00 – 13:00 Lunch 
 
13:00 – 15:20 Oral Session 2 – Managing Products in a Complex Environment 
 Chair: Stefanie Pluschkell, Executive Director, Pfizer 
 
13:00 – 13:50 Plenary Lecture: Title TBA 
Jeff Baker, FDA  
 
13:50 – 14:20 Innovation and continuous improvement in a seemingly accelerated regulatory environment 
 Roger Nosal, Pfizer Inc 
  
14:20 – 14:50 Managing CMC for global accelerated marketing approvals  
Pradip Ghosh-Dastidar, BMS, presenting on behalf of IFPMA 
  
14:50 – 15:20 PATH - A global health nonprofit organization in support of international vaccine manufacturing 
George Robertson, PATH 
 
15:20 – 16:00 Coffee break 
 
16:00 – 18:00 Workshops 
Workshop 1 – National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) 
(Chairs: Barry Buckland, Stacy Springs and Louise Johnson, NIIMBL) 
Workshop 2 – Managing Complexity 
(Chairs: Steffi Pluschkell, Pfizer, and Kumar Namdev, Sanofi) 
 
18:00 – 19:00 Dinner 
 
Monday, April 24, 2017 (continued) 
 
19:00 – 21:00 Oral Session 3 – Accelerating Development 
 Chair: Tony Mire-Sluis, Head of Global Quality, AstraZeneca 
 
19:10 – 20:00 Plenary Lecture – Leveraging knowledge to accelerate the development of biological products 
Tony Mire Sluis, Head of Global Quality, Astra Zeneca 
 
20:00 – 20:30 Accelerating strategies for FIH process development 
Margaret Ricci, Amgen 
 
20:30 – 21:00 Systems analysis and design for accelerating process and cell line development 
 Wei-Shou Hu, University of Minnesota 
 
21:00 – 21:15 Rapid Fire Oral Presentations/Poster Session Preview 
 Chair: Sevda Deldari, UMBC 
 





Tuesday, April 25, 2017 
 
07:30 – 08:30 Breakfast 
 
08:30 – 12:00 Oral Session 4 – Approaches to innovative and streamlined manufacturing,  
Chair: Aine Hanly, VP Drug Substance Technologies & Site Head Amgen Cambridge 
 
08:40 – 09:30 Plenary Lecture – Accelerating development and managing risk 
Tony Lubiniecki, Senior Fellow, Janssen Pharmaceuticals R&D 
 
09:30 – 10:00 Managing and Mitigating Risk in Biologics Process Transfer 
Charles Goochee, Janssen Pharmaceuticals 
 
10:00 – 10:30 Coffee break (Sponsored by Amgen) 
 
10:30 – 11:00  Transforming operations with next generation Biomanufacturing 
Arleen Paulino, Amgen Singapore  
 
11:00 – 11:30 Lifecycle approach to validation supports accelerated approvals 
Julia O’Neill, Tunnell Consulting 
  
11:30 – 12:00 Continuous bioprocessing: Technology and regulatory challenges and mitigation strategies 
Mani Krishnan, Pall Lifesciences 
 
12:00 – 13:00 Lunch 
 
13:00 – 15:00 Oral Session 5 – It’s All About the Analytics 
Chair: Mark Schenerman, Vice President, MedImmune  
 
13:00 – 13:30 An FDA perspective on the implementation of state-of-the-art analytical methods for 
therapeutic proteins 
Marjorie Shapiro, FDA  
  
13:30 – 14:00 Modernizing analytics for improved manufacturing efficiency – regulatory considerations 
Steven Rubin, FDA  
  
14:00 – 14:30 Physicochemical assays and characterization 
Yang Wang, MedImmune  
  
14:30 – 15:00 Bioassays and Effector Function 
Raju Shantha, MedImmune 
 
15:00 – 15:30 Coffee break 
 
15:30 – 17:30 Workshops 
Workshop 3 – It’s all about the analytics 
(Chair: Mark Schenerman, MedImmune) 
Workshop 4 – Hot topics 
(Chair: Beth Junker, Bioprocess Advantage) 
 
17:30 – 18:00 Coffee break 
 
Tuesday, April 25, 2017 (continued) 
 
18:00 – 19:00 Keynote Lecture 3, Regulatory Sciences from a Regulator’s, an Industrialist’s and an 
Academic’s Perspective 
Robert Meyer, Virginia Center for Translational and Regulatory Sciences, University of Virginia  
 
19:00 – 19:15 Rapid Fire Oral Presentations/Poster Session Preview 
Chair: Sevda Deldari, UMBC 
 
19:15 – 20:30 Dinner 
 







Wednesday, April 26, 2017 
 
07:30 – 08:30 Breakfast 
 
08:30 – 09:30 Keynote 4, Steven Kozlowski, FDA  
 
09:30 – 10:00 Coffee break 
 
10:00 – 12:30 Oral Session 6 – Risk-based characterization 
 Chairs: Thomas Ryll, Vice President, Immunogen and Jose Menezes, Professor, Instituto 
Superior Técnico, Portugal 
 
10:00 – 10:30 Leveraging Mab cell culture platform to predict product quality 
 Chris Kwiatkowski, Biogen 
 
10:30 – 11:00 Comparability and similarity protocols for biotechnology products 
 Francisca F. Gouveia, Pedro M. Felizardo, and José C. Menezes, 4Tune Engineering Ltd. 
 
11:00 – 11:30 Pre-clinical to Phase III upstream process changes to support next generation manufacturing 
 Sarwat Khattak, Biogen 
 
11:30 – 12:00 Comparability assessment of an antibody-drug conjugate (ADC) 
 Alex Lazar, ImmunoGen 
 
12:00 – 12:30 Global implementation of a cell culture change: Strategies, lessons learned and challenges 
 Marie-Pierre Gentile, Genentech 
 
12:30 – 12:45 Closing Comments: Tony Moreira and David Robinson 
 




1.  Influenza hemagglutinin glycoproteins with different N-glycan patterns activate 
dendritic cells in vitro 
Suh-Chin Wu, Institute of Biotechnology, National Tsing Hua University, Taiwan 
 
2.  Rapid transient and stable protein production with consistent quality to accelerate 
biotherapeutic development 
Weili Wang, MaxCyte, Inc., USA  
 
3.  Streamlining viral clearance strategy with generic claims and worst case studies 
Brad Stanley, Biogen, USA 
 
4.  Utility of GMP Next Generation Sequencing (NGS) for biosafety assesment of 
biological products 
Audrey Chang, BioReliance/MilliporeSigma, USA 
 
5.  Defining established conditions under ICH Q12 for Pre-QbD commercial products 
Jose Menezes, 4Tune Engineering Ltd, Portugal 
 
6.  Critical considerations in bioreactor design to optimize cell-free protein expression in 
CHO 
Chariz Johnstone, University of Maryland Baltimore County, USA 
 
7.  Reactivity and specificity of mice antisera generated from Coxsackievirus A6 and A10 
vaccinations 
Chia-Chyi Liu, National Health Research Institutes, Taiwan 
 
8.  Platform analytical methods approach “compendial-like” status 
Carrie R. Lewis, MedImmune, USA 
 
9.  Development and validation of an IMAC purification platform for His-tagged proteins 
expressed in a CHO cell-free system 
Sevda Deldari, University of Maryland Baltimore County, USA 
 
10.  Transferring methods for vaccine release between the industry, academy and a 
regulatory agency: Lessons learned 
Elizabeth Carrasco, LAMMB, Instituto de Biotecnología, Mexico 
 
11.  Impact of a mutation in the podB gene on protein productivity in filamentous fungi 
Karthik R. Boppidi, University of Maryland Baltimore County, USA  
 
12.  Fundamental studies of the mechanism of Ion exchange chromatography 
Payam Rezaei, University of Maryland Baltimore County, USA  
 
13.  NIIMBL: The National Institute for Innovation in Manufacturing Biopharmaceuticals 
Barry Buckland, BiologicB, USA 
 
14.  Expression and purification of highly complex therapeutics, tPA in a mammalian cell-
free expression system 
David Burgenson, University of Maryland Baltimore County, USA 
 
15.  Process development tools and initial results for the purification of therapeutic 
antibody products with neutral to acidic pI values using a non-affinity capture method 
Yang Liu, University of Maryland Baltimore County, USA 
 
